Intervention Review

Tamoxifen for relapse of ovarian cancer

  1. Chris Williams1,*,
  2. Iveta Simera2,
  3. Andrew Bryant3

Editorial Group: Cochrane Gynaecological Cancer Group

Published Online: 17 MAR 2010

Assessed as up-to-date: 1 FEB 2010

DOI: 10.1002/14651858.CD001034.pub2


How to Cite

Williams C, Simera I, Bryant A. Tamoxifen for relapse of ovarian cancer. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No.: CD001034. DOI: 10.1002/14651858.CD001034.pub2.

Author Information

  1. 1

    Royal United Hospital, Cochrane Gynaecological Cancer Review Group, Bath, UK

  2. 2

    NDORMS, University of Oxford, Centre for Statistics in Medicine, Oxford, UK

  3. 3

    Newcastle University, Institute of Health & Society, Newcastle upon Tyne, UK

*Chris Williams, Cochrane Gynaecological Cancer Review Group, Royal United Hospital, Combe Park, Bath, BA1 3NG, UK. chrisjhwilliams@btinternet.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 17 MAR 2010

SEARCH

  1. Current Version

    Tamoxifen for relapse of ovarian cancer

    Chris Williams, Iveta Simera and Andrew Bryant

    Article first published online: 17 MAR 2010 | DOI: 10.1002/14651858.CD001034.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Tamoxifen for relapse of ovarian cancer

    Chris Williams and Iveta Simera

    Article first published online: 22 JAN 2001 | DOI: 10.1002/14651858.CD001034